PIKFYVE and prostate cancer: Importantly, the increased MHC-I surface expression by PIKfyve inhibition was also observed in various human cancer models, including MIA PaCa2, LNCaP, and prostate cancer patient–derived xenografts (SI Appendix, Fig. S1 B–D).